Allograft Dysfunction in Heart Transplant
Recruiting · NCT03102125 · Interventional (participants receive a specific treatment) · Lead sponsor: Paul Kim
View the official record on ClinicalTrials.gov →Interventions studied
Regadenoson
What this trial is about
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age greater than or equal to 18 years old.
- At least three months status post heart transplantation.
Exclusion criteria
- Biopsy proven acute rejection episode in the past 3 months.
- Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
- Uncontrolled obstructive ventilatory disease including asthma and COPD.
- History of generalized tonic-clonic seizures.
- Second or third degree AV nodal block.
- Sinus node dysfunction.
- Contraindications to MRI including cardiovascular implantable electronic devices.
- Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.
- Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.
- Systolic blood pressure greater than 180 or less than 85 mmHg.
- Diastolic blood pressure greater than 120 or less than 40 mmHg.
- Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.
Where it is running
1 location listed across 1 US state.
- UC San Diego - La Jolla, California, United States